Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion

Journal of Urology

Volumn 187, Issue 3, 2012, Pages 795-801

  Salagierski, MacIej ^a,b   Schalken, Jack A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

gene fusion; human; prostate; prostate cancer antigen 3; prostatic neoplasms; TMPRSS2 ERG fusion protein

Indexed keywords

CANCER STAGING; CHROMOSOME 21; DIAGNOSTIC ACCURACY; DNA STRAND BREAKAGE; ERG GENE; GENE; GENE FUSION; GENE STRUCTURE; GLEASON SCORE; HUMAN; MOLECULAR DIAGNOSIS; NOMOGRAM; PCA3 GENE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY; TMPRSS2 GENE; UPREGULATION;

ANTIGENS, NEOPLASM; BIOPSY; HUMANS; MALE; ONCOGENE PROTEINS, FUSION; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84857044547     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2011.10.133     Document Type: Review

References (48)

1. A. Jemal, R. Siegel, J. Xu Cancer statistics, 2010 CA Cancer J Clin 60 2010 277
2. J. Groskopf, S.M. Aubin, L. Deras APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer Clin Chem 52 2006 1089
3. R.S. Tuma New tests for prostate cancer may be nearing the clinic J Natl Cancer Inst 102 2010 752
4. M.J. Bussemakers, A. van Bokhoven, G.W. Verhaegh DD3: a new prostate-specific gene, highly overexpressed in prostate cancer Cancer Res 59 1999 5975
5. G.W. Verhaegh, A. van Bokhoven, F. Smit Isolation and characterization of the promoter of the human prostate cancer-specific DD3 gene J Biol Chem 275 2000 37496
6. D. Hessels, J.M. Klein Gunnewiek, I. van Oort DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer Eur Urol 44 2003 8
7. J.A. Schalken, D. Hessels, G. Verhaegh New targets for therapy in prostate cancer: differential display code 3 (DD3(PCA3)), a highly prostate cancer-specific gene Urology 62 2003 34
8. I.L. Deras, S.M. Aubin, A. Blase PCA3: a molecular urine assay for predicting prostate biopsy outcome J Urol 179 2008 1587
9. M.J. Roobol, F.H. Schrder, G.L. van Leenders Performance of prostate cancer antigen 3 (PCA3) and prostate-specific antigen in prescreened men: reproducibility and detection characteristics for prostate cancer patients with high PCA3 scores (<100) Eur Urol 58 2010 893
10. M.P. van Gils, D. Hessels, O. van Hooij The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance Clin Cancer Res 13 2007 939
11. A. Haese, A. de la Taille, H. van Poppel Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy Eur Urol 54 2008 1081
12. M.J. Roobol, F.H. Schrder, P. van Leeuwen Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test Eur Urol 58 2010 475
13. F.K. Chun, A. de la Taille, H. van Poppel Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram Eur Urol 56 2009 659
14. M. Auprich, A. Haese, J. Walz External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome Eur Urol 58 2010 727
15. D.P. Ankerst, J. Groskopf, J.R. Day Predicting prostate cancer risk through incorporation of prostate cancer gene 3 J Urol 180 2008 1303
16. S. Perdon, V. Cavadas, G. Di Lorenzo Prostate cancer detection in the "grey area" of prostate-specific antigen below 10 ng/ml: head-to-head comparison of the updated PCPT calculator and Chun's nomogram, two risk estimators incorporating prostate cancer antigen 3 Eur Urol 59 2011 81
17. D. Hessels, M.P. van Gils, O. van Hooij Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer Prostate 70 2010 10
18. M.P. van Gils, D. Hessels, C.A. Hulsbergen-van de Kaa Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results Prostate 68 2008 1215
19. M.A. Liss, R. Santos, K. Osann PCA3 molecular urine assay for prostate cancer: association with pathologic features and impact of collection protocols World J Urol 29 2011 683
20. H. Nakanishi, J. Groskopf, H.A. Fritsche PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance J Urol 179 2008 1804
21. L.S. Marks, Y. Fradet, I.L. Deras PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy Urology 69 2007 532
22. E.J. Whitman, J. Groskopf, A. Ali PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume J Urol 180 2008 1975
23. M. Auprich, F.K. Chun, J.F. Ward Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging Eur Urol 59 2011 96
24. I. Popa, Y. Fradet, G. Beaudry Identification of PCA3 (DD3) in prostatic carcinoma by in situ hybridization Mod Pathol 20 2007 1121
25. F. Mitelman, B. Johansson, F. Mertens The impact of translocations and gene fusions on cancer causation Nat Rev Cancer 7 2007 233
26. M. Hglund, A. Frigyesi, F. Mitelman A gene fusion network in human neoplasia Oncogene 25 2006 2674
27. A.M. Chinnaiyan, N. Palanisamy Chromosomal aberrations in solid tumors Prog Mol Biol Transl Sci 95 2010 55
28. S. Perner, J.M. Mosquera, F. Demichelis TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion Am J Surg Pathol 31 2007 882
29. S. Perner, F. Demichelis, R. Beroukhim TMPRSS2: ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer Cancer Res 66 2006 8337
30. M.C. Haffner, M.J. Aryee, A. Toubaji Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements Nat Genet 42 2010 668
31. D. Hessels, F.P. Smit, G.W. Verhaegh Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer Clin Cancer Res 13 2007 5103
32. R.J. Karnes, J.C. Cheville, C.M. Ida The ability of biomarkers to predict systemic progression in men with high-risk prostate cancer treated surgically is dependent on ERG status Cancer Res 70 2010 8994
33. F. Demichelis, K. Fall, S. Perner TMPRSS2: ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort Oncogene 26 2007 4596
34. G. Attard, J. Clark, L. Ambroisine Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer Oncogene 27 2008 253
35. A. Gopalan, M.A. Leversha, J.M. Satagopan TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy Cancer Res 69 2009 1400
36. J. Rubio-Briones, A. Fernndez-Serra, A. Calatrava Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy J Urol 183 2010 2054
37. G. Attard, J.F. Swennenhuis, D. Olmos Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer Cancer Res 69 2009 2912
38. G. Attard, A.H. Reid, T.A. Yap Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven J Clin Oncol 26 2008 4563
39. J. Wang, Y. Cai, W. Yu Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts Cancer Res 68 2008 8516
40. J.P. Clark, K.W. Munson, J.W. Gu Performance of a single assay for both type III and type VI TMPRSS2: ERG fusions in noninvasive prediction of prostate biopsy outcome Clin Chem 54 2008 2007
41. B. Laxman, D.S. Morris, J. Yu A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer Cancer Res 68 2008 645
42. G. Petrovics, A. Liu, S. Shaheduzzaman Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome Oncogene 24 2005 3847
43. D.L. Cao, D.W. Ye, H.L. Zhang A multiplex model of combining gene-based, protein-based, and metabolite-based with positive and negative markers in urine for the early diagnosis of prostate cancer Prostate 71 2010 700
44. A.P. Khan, L.M. Poisson, V.B. Bhat Quantitative proteomic profiling of prostate cancer reveals a role for miR-128 in prostate cancer Mol Cell Proteomics 9 2010 298
45. A. Sreekumar, L.M. Poisson, T.M. Rajendiran Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression Nature 457 2009 910
46. F. Jentzmik, C. Stephan, M. Lein Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression J Urol 185 2011 706
47. D. Hessels, J.A. Schalken The use of PCA3 in the diagnosis of prostate cancer Nat Rev Urol 6 2009 255
48. S.A. Tomlins, A. Bjartell, A.M. Chinnaiyan ETS gene fusions in prostate cancer: from discovery to daily clinical practice Eur Urol 56 2009 275